Nuove specialità medicinali: Mounjaro, Opdualag, Pyzchiva, Salmeterolo E Fluticasone Teva Italia. 7 Nuovi farmaci equivalenti
Sugli scaffali delle farmacie arrivano nuovi farmaci. Ecco la lista aggiornata.
MOUNJARO KWIKPEN 1 penna preriempita SC 2,5 mg 2,4 ml tirzepatide
ELI LILLY AIC:050357490 346,58€ Cnn/RR in commercio dal:03/10/2024
MOUNJARO KWIKPEN 1 penna preriempita SC 5 mg 2,4 ml tirzepatide
ELI LILLY AIC:050357514 346,58€ Cnn/RR in commercio dal:03/10/2024
OPDUALAG 1 flaconcino INFUS 240 mg + 80 mg 20 ml nivolumab/relatlimab
BRISTOL-MYERS SQUIBB AIC:050359013 10.696,03€ H/OSP in commercio dal:21/10/2024
PYZCHIVA 1 flaconcino EV 130 mg 26 ml ustekinumab
SAMSUNG BIOEPIS AIC:051202036 3.753,53€ H/RRL in commercio dal:30/09/2024
PYZCHIVA 1 siringa SC 45 mg 0,5 ml ustekinumab
SAMSUNG BIOEPIS AIC:051202012 3.753,53€ H/RRL in commercio dal:30/09/2024
PYZCHIVA 1 siringa SC 90 mg 1 ml ustekinumab
SAMSUNG BIOEPIS AIC:051202024 3.753,53€ H/RRL in commercio dal:30/09/2024
SALMETEROLO E FLUTICASONE TEVA ITALIA polv inal 1 inalatore 60 dosi 50 mcg + 250 mcg salmeterolo xinafoato/fluticasone propionato
TEVA AIC:050478015 25,92€ A/RR in commercio dal:03/10/2024
SALMETEROLO E FLUTICASONE TEVA ITALIA polv inal 1 inalatore 60 dosi 50 mcg + 500 mcg salmeterolo xinafoato/fluticasone propionato
TEVA AIC:050478027 32,50€ A/RR in commercio dal:03/10/2024
Nuovi farmaci equivalenti
BOSUTINIB DR. REDDY’S 28 cpr riv 100 mg bosutinib
DR. REDDY’S AIC:051018012 1.080,19€ Cnn/RNRL in commercio dal:27/09/2024
BOSUTINIB DR. REDDY’S 28 cpr riv 400 mg bosutinib
DR. REDDY’S AIC:051018051 4.320,70€ Cnn/RNRL in commercio dal:27/09/2024
BOSUTINIB DR. REDDY’S 28 cpr riv 500 mg bosutinib
DR. REDDY’S AIC:051018087 4.320,70€ Cnn/RNRL in commercio dal:27/09/2024
CEFTRIAXONE KALCEKS 10 flaconcini polv EV 1 g ceftriaxone disodico
AS KALCEKS AIC:050414022 74,32€ Cnn/RNRL in commercio dal:30/09/2024
RANOLAZINA TEVA 60 cpr 375 mg rilascio prolungato ranolazina
TEVA AIC:050945056 15,20€ A/RR in commercio dal:03/10/2024
RANOLAZINA TEVA 60 cpr 500 mg rilascio prolungato ranolazina
TEVA AIC:050945118 15,20€ A/RR in commercio dal:03/10/2024
RANOLAZINA TEVA 60 cpr 750 mg rilascio prolungato ranolazina
TEVA AIC:050945171 15,20€ A/RR in commercio dal:03/10/2024